Capital Performance Advisors LLP Akebia Therapeutics, Inc. Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 68 shares of AKBA stock, worth $127. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68Holding current value
$127% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AKBA
# of Institutions
121Shares Held
54.8MCall Options Held
291KPut Options Held
179K-
Black Rock Inc. New York, NY11.6MShares$21.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$18.9 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$10.8 Million13.23% of portfolio
-
Geode Capital Management, LLC Boston, MA4.75MShares$8.94 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.72MShares$6.99 Million0.01% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $346M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...